Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21


Genetic Diversity of Cryptosporidium hominis in a Bangladeshi Community as Revealed by Whole-Genome Sequencing.

Gilchrist CA, Cotton JA, Burkey C, Arju T, Gilmartin A, Lin Y, Ahmed E, Steiner K, Alam M, Ahmed S, Robinson G, Zaman SU, Kabir M, Sanders M, Chalmers RM, Ahmed T, Ma JZ, Haque R, Faruque ASG, Berriman M, Petri WA.

J Infect Dis. 2018 Jun 20;218(2):259-264. doi: 10.1093/infdis/jiy121.


Exploring the mechanism of amebic trogocytosis: the role of amebic lysosomes.

Gilmartin AA, Petri WA Jr.

Microb Cell. 2017 Dec 6;5(1):1-3. doi: 10.15698/mic2018.01.606. No abstract available.


Inhibition of Amebic Lysosomal Acidification Blocks Amebic Trogocytosis and Cell Killing.

Gilmartin AA, Ralston KS, Petri WA Jr.

MBio. 2017 Aug 29;8(4). pii: e01187-17. doi: 10.1128/mBio.01187-17.


Pharmacological inhibition of fatty acid amide hydrolase attenuates social behavioural deficits in male rats prenatally exposed to valproic acid.

Kerr DM, Gilmartin A, Roche M.

Pharmacol Res. 2016 Nov;113(Pt A):228-235. doi: 10.1016/j.phrs.2016.08.033. Epub 2016 Aug 31.


Exploring the role of environmental enteropathy in malnutrition, infant development and oral vaccine response.

Gilmartin AA, Petri WA Jr.

Philos Trans R Soc Lond B Biol Sci. 2015 Jun 19;370(1671). pii: 20140143. doi: 10.1098/rstb.2014.0143. Review.


WIP1 phosphatase as a potential therapeutic target in neuroblastoma.

Richter M, Dayaram T, Gilmartin AG, Ganji G, Pemmasani SK, Van Der Key H, Shohet JM, Donehower LA, Kumar R.

PLoS One. 2015 Feb 6;10(2):e0115635. doi: 10.1371/journal.pone.0115635. eCollection 2015.


Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction.

Gilmartin AG, Faitg TH, Richter M, Groy A, Seefeld MA, Darcy MG, Peng X, Federowicz K, Yang J, Zhang SY, Minthorn E, Jaworski JP, Schaber M, Martens S, McNulty DE, Sinnamon RH, Zhang H, Kirkpatrick RB, Nevins N, Cui G, Pietrak B, Diaz E, Jones A, Brandt M, Schwartz B, Heerding DA, Kumar R.

Nat Chem Biol. 2014 Mar;10(3):181-7. doi: 10.1038/nchembio.1427. Epub 2014 Jan 5.


Will nanomedicine deliver on its promise of changing therapeutics or remain an interesting and important research tool in cell biology and physiology?

Kirsh R, Hood S, Brook C, Gilmartin A, Dell'orco P, Meek T.

Int J Pharm. 2013 Sep 15;454(1):530-1. doi: 10.1016/j.ijpharm.2013.06.042. Epub 2013 Jun 28. No abstract available.


Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212.

Jing J, Greshock J, Holbrook JD, Gilmartin A, Zhang X, McNeil E, Conway T, Moy C, Laquerre S, Bachman K, Wooster R, Degenhardt Y.

Mol Cancer Ther. 2012 Mar;11(3):720-9. doi: 10.1158/1535-7163.MCT-11-0505. Epub 2011 Dec 14.


High-level secretion of recombinant monomeric murine and human single-chain Fv antibodies from Drosophila S2 cells.

Gilmartin AA, Lamp B, Rümenapf T, Persson MA, Rey FA, Krey T.

Protein Eng Des Sel. 2012 Feb;25(2):59-66. doi: 10.1093/protein/gzr058. Epub 2011 Dec 12.


Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate).

Abe H, Kikuchi S, Hayakawa K, Iida T, Nagahashi N, Maeda K, Sakamoto J, Matsumoto N, Miura T, Matsumura K, Seki N, Inaba T, Kawasaki H, Yamaguchi T, Kakefuda R, Nanayama T, Kurachi H, Hori Y, Yoshida T, Kakegawa J, Watanabe Y, Gilmartin AG, Richter MC, Moss KG, Laquerre SG.

ACS Med Chem Lett. 2011 Feb 28;2(4):320-4. doi: 10.1021/ml200004g. eCollection 2011 Apr 14.


GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.

Gilmartin AG, Bleam MR, Groy A, Moss KG, Minthorn EA, Kulkarni SG, Rominger CM, Erskine S, Fisher KE, Yang J, Zappacosta F, Annan R, Sutton D, Laquerre SG.

Clin Cancer Res. 2011 Mar 1;17(5):989-1000. doi: 10.1158/1078-0432.CCR-10-2200. Epub 2011 Jan 18. Erratum in: Clin Cancer Res. 2012 Apr 15;18(8):2413.


Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability.

Degenhardt Y, Greshock J, Laquerre S, Gilmartin AG, Jing J, Richter M, Zhang X, Bleam M, Halsey W, Hughes A, Moy C, Liu-Sullivan N, Powers S, Bachman K, Jackson J, Weber B, Wooster R.

Mol Cancer Ther. 2010 Jul;9(7):2079-89. doi: 10.1158/1535-7163.MCT-10-0095. Epub 2010 Jun 22.


Antitumor activity of an allosteric inhibitor of centromere-associated protein-E.

Wood KW, Lad L, Luo L, Qian X, Knight SD, Nevins N, Brejc K, Sutton D, Gilmartin AG, Chua PR, Desai R, Schauer SP, McNulty DE, Annan RS, Belmont LD, Garcia C, Lee Y, Diamond MA, Faucette LF, Giardiniere M, Zhang S, Sun CM, Vidal JD, Lichtsteiner S, Cornwell WD, Greshock JD, Wooster RF, Finer JT, Copeland RA, Huang PS, Morgans DJ Jr, Dhanak D, Bergnes G, Sakowicz R, Jackson JR.

Proc Natl Acad Sci U S A. 2010 Mar 30;107(13):5839-44. doi: 10.1073/pnas.0915068107. Epub 2010 Feb 18.


Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis.

Gilmartin AG, Bleam MR, Richter MC, Erskine SG, Kruger RG, Madden L, Hassler DF, Smith GK, Gontarek RR, Courtney MP, Sutton D, Diamond MA, Jackson JR, Laquerre SG.

Cancer Res. 2009 Sep 1;69(17):6969-77. doi: 10.1158/0008-5472.CAN-09-0945. Epub 2009 Aug 18.


Evidence for allosteric interactions of antagonist binding to the smoothened receptor.

Rominger CM, Bee WL, Copeland RA, Davenport EA, Gilmartin A, Gontarek R, Hornberger KR, Kallal LA, Lai Z, Lawrie K, Lu Q, McMillan L, Truong M, Tummino PJ, Turunen B, Will M, Zuercher WJ, Rominger DH.

J Pharmacol Exp Ther. 2009 Jun;329(3):995-1005. doi: 10.1124/jpet.109.152090. Epub 2009 Mar 20. Erratum in: J Pharmacol Exp Ther. 2010 Feb;332(2):690.


Gestational diabetes mellitus.

Gilmartin AB, Ural SH, Repke JT.

Rev Obstet Gynecol. 2008 Summer;1(3):129-34.


TNF-alpha modulates angiopoietin-1 expression in rheumatoid synovial fibroblasts via the NF-kappa B signalling pathway.

Scott BB, Zaratin PF, Gilmartin AG, Hansbury MJ, Colombo A, Belpasso C, Winkler JD, Jackson JR.

Biochem Biophys Res Commun. 2005 Mar 11;328(2):409-14.


An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage.

Jackson JR, Gilmartin A, Imburgia C, Winkler JD, Marshall LA, Roshak A.

Cancer Res. 2000 Feb 1;60(3):566-72.



Rohlf FJ, Gilmartin AJ, Hart G.

Evolution. 1983 Jan;37(1):180-202. doi: 10.1111/j.1558-5646.1983.tb05526.x. No abstract available.


Supplemental Content

Loading ...
Support Center